July 15, 2019 – A paper about the University of Sydney and NSW Health clinical trial provides the first strong evidence that so-called cannabinoid agonist medication — which targets receptors in the brain — could reduce the rate of relapse. The paper published today in the American Medical Association’s JAMA Internal Medicine. Lead author Conjoint Professor Nick Lintzeris — of the University of Sydney’s Faculty of Medicine and Health and Director of Drug & Alcohol Services, South East Sydney Local Health District — said the study should give hope to people with dependency on cannabis, which is a leading cause of drug treatment episodes in Australia.*
“We’ve never had the evidence before that medication can be effective in treating cannabis dependency — this is the first big study to show this is a safe and effective approach,” Professor Lintzeris said. “The principles are very similar to nicotine replacement; you are providing patients with a medicine which is safer than the drug they’re already using, and linking this with medical and counselling support to help people address their illicit cannabis use.
GIVING BACK IN STYLE – April 17, 2024 - “It’s still one day at…
RIDING THE WAVE...CALMLY – April 18, 2024 - “I was 13 years old and…
VIDEO – NEW YORK STORIES – April 23, 2024 - Sara Gettelfinger had steadily…
TRY IT, YOU’LL LIKE IT – April 18, 2024 - The rise in “sober…
AUDIO – SOBER MEN CAN DO THAT – April 4, 2024 - Acting icon…
I’LL BET HE GOES TO GA (not Georgia) – April 13, 2024 -The initial…